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ABSTRACT
IMPACT OF MACULAR PIGMENT OPTICAL DENSITY ON PHOTOPHOBIA
THRESHOLD
by
Adam J. Wenzel 
University of New Hampshire, September, 2004
Two carotenoids, lutein and zeaxanthin, accumulate in the central retina where 
they are collectively referred to as macular pigment (MP). By absorbing short- 
wavelength light, MP may attenuate photophobia (PP)—visual discomfort induced by 
normal light exposure—for targets composed of short-wavelength light. The aim of this 
study was twofold: first, to investigate a possible relationship between integrated macular 
pigment optical density (MPOD) and PP thresholds for short-wavelength targets relative 
to mid- to long-wavelength targets; and second, to measure changes in PP thresholds after 
increasing MP with lutein supplements.
MPOD was measured psychophysically at 20', 30', 60' and 120' eccentricity with 
a Macular Metrics® densitometer. Each subject’s MPOD profile was fit with a Gaussian 
and Lorentzian function and the area under the curve was calculated to yield an integrated 
Gaussian MPOD (iGMPOD) or integrated Lorentzian MPOD (iLMPOD). PP thresholds 
for two foveal and two parafoveal, 8.2-degree targets were measured using a Maxwellian- 
view optical system. At both loci, a scaling technique was used to measure subjects’ 
level of discomfort for a short-wavelength broadband (blue) light, which was strongly 
absorbed by MP, and a mid- to long-wavelength broadband (orange) light, which was not 
absorbed my MP. For both eccentricities, the log relative energy necessary to induce PP 
for the blue target was subtracted from the log relative energy necessary for the orange
x
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target. The foveal value was then subtracted from the parafoveal value to yield a PP 
ratio. PP ratios and iGMPOD and iLMPOD were calculated for ten subjects. Repeated 
measures were obtained for four of these subjects after six weeks and twelve weeks of 
consuming 60mg of lutein ester supplements per day.
PP ratios were positively correlated with iGMPOD (r=0.830, p=0.002) and 
iLMPOD (r=0.775, p=0.008). According to a subjects-by-trials design, both iGMPOD 
(F=9.12, p=0.015) and iLMPOD (F=17.35, p=0.003) significantly increased from 
baseline. Significant increases in integrated MPOD corresponded to significant increases 
in PP ratio (F=10.41, p=0.036).
The results suggest that MPOD may influence the amount of short-wavelength 
light necessary to elicit PP. Further, PP thresholds for short-wavelength lights can be 
increased by augmenting MPOD with lutein supplementation.
xi
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CHAPTER I
RETINAL CAROTENOIDS
Carotenoids are a class of naturally derived pigments synthesized by various 
plants and protists. The basic structure of all carotenoids is a string of isoprene units.
The majority of identified carotenoids have a six-carbon ring at each end of a carbon 
chain, which may include one or more oxygen groups. If the carbon ring contains 
oxygen, the carotenoid is referred to as a xanthophyll (e.g., lutein and zeaxanthin), 
otherwise it is called a carotene (e.g., p-carotene).
In plant systems, carotenoids appear to be synthesized to protect the organism via 
two physiological reactions. First, carotenoids’ chain of conjugated double-bonds allows 
them to transfer energy from singlet oxygen and other free radical species, effectively 
quenching these noxious species. Second, carotenoids absorb light in the potentially 
harmful, short-wavelength (SW) region of the spectrum and dissipate the energy as heat. 
Carotenoids consumed in the diet may play these same beneficial roles in humans and 
other animals. In fact, epidemiology studies have repeatedly found correlations between 
carotenoid rich diets and good health. Specifically, carotenoid intake has been linked 
with a lower risk for atherosclerosis (Dwyer et al., 2001; Gale et al., 2001) as well as 
various types of cancers, such as prostate cancer (Lindsey 2002; Miller et al., 2002), 
breast cancer (Johnson, 2000) and ovarian cancer (Huncharek et al., 2001). Dietary 
carotenoids may also reduce one’s risk of developing cataract and age-related macular
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
degeneration (AMD; Moeller et al., 2000), two leading causes o f blindness (Robinson et 
al., 1997; AREDS, 2000).
Two carotenoids are primarily associated with preventing cataractogenesis and 
AMD, lutein and zeaxanthin. These two plant pigments are found in a variety of fruits 
and green, leafy vegetables commonly consumed in the human diet (Khachik et al., 
1992a; 1992b; Sommerburg et al., 1998). The absorption of lutein and zeaxanthin occurs 
in the duodenum, where the carotenoids are released from their food matrices and 
incorporated into micelles. Some of these micelles may transfer the carotenoids to 
mucosal cells, via passive diffusion, whereas other carotenoid-containing micelles are 
unabsorbed (Parker, 1996). After entering the enterocyte, lutein and zeaxanthin are 
incorporated into chylomicra and then released into the blood stream. The carotenoid 
concentration in chylomicra peaks approximately four to eight hours after intake (Yeum 
& Russell, 2002). Circulating chylomicra are degraded by lipoprotein lipase and the 
chylomicron remnants are collected by the liver. In the liver, carotenoids are repackaged 
within lipoproteins. Some carotenoids, like P-carotene, are predominately distributed in 
low-density lipoproteins (LDL), whereas lutein and zeaxanthin are distributed evenly 
between LDL and high-density lipoproteins (HDL; Yeum & Russell, 2002). The 
carotenoid concentration in lipoproteins peaks approximately 16 to 48 hours after 
ingestion (Erdman et al., 1993).
The absorption, or bioavailability, of carotenoids is influenced by several factors 
(see van het Hof et al., 2000). For example, dietary fat must be consumed concurrently 
with carotenoids in order to stimulate micelle formation. In the absence of dietary fat, 
carotenoid absorption may be as low as 5%, whereas a small amount of fat may increase
2
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absorption to approximately 45% (Ribaya-Mercado, 2002). Unlike other carotenoids that 
may be optimally absorbed when consumed with a limited amount of fat, one study 
reported that lutein absorption was significantly greater in individuals who consumed a 
lutein supplement with 34.4g of fat daily for seven-days, compared to individuals who 
consumed the lutein with 3g of fat (Roodenburg et al., 2000). Another factor that affects 
the absorption of carotenoids is the food matrix containing the carotenoid. Generally, 
absorption of carotenoids is greater when they are suspended in an oil solution (i.e., 
supplements), as opposed to raw vegetables (van het Hof et al., 1999). Processing of raw 
vegetables, on the other hand, may increase the bioavailability of some carotenoids. 
Castenmiller et al. (1999) showed that processing raw spinach improved the 
bioavailability of p-carotene, but had little effect on lutein absorption. The absorption of 
carotenoids is also affected by the interaction or competition between carotenoids in the 
lumen and enterocytes. A number of researchers has shown that coincident consumption 
of lutein with other carotenoids may impair lutein absorption (see van den Berg, 1999). 
Tyssandier et al. (2002), for example, reported that chylomicron lutein levels were 
diminished when lutein (from spinach) was consumed with lycopene supplements. 
Conversely, Gartner et al. (1996) showed that after consuming a single dose of 
Betatene™—a natural extract containing lutein, zeaxanthin, a-carotene and p-carotene— 
the chylomicron distribution of lutein was fourteen times greater than its relative 
concentration in the supplement; the zeaxanthin distribution was four times greater than 
its relative concentration.
Carotenoids are transported through the body in lipoproteins, and via unrealized 
mechanisms, deposited in lipophilic tissues such as adipose tissue and various immune
3
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organs (Olsen, 1984). Lutein and zeaxanthin, to the exclusion of other carotenoids, cross 
the blood-retinal barrier and are deposited in the inner plexiform (i.e., ganglion dendrites 
and bipolar cell extensions) and photoreceptor-axonal layers (Snodderly et al., 1984). 
Although the exact mechanisms mediating this retinal accumulation are unknown, 
Bernstein et al. (1997) suggested that specific lutein and zeaxanthin retinal binding 
proteins, perhaps tubulin, may be responsible.
Lutein and zeaxanthin accumulate throughout the entire human retina 
(Handelman et al., 1988). Using high-performance liquid chromatography, researchers 
have estimated that the total retinal concentrations of lutein and zeaxanthin are between 4 
and 145ng, with lutein accounting for approximately two-thirds of the combined tissue 
concentration (Bone et al., 1988; Rapp et al., 2000). These carotenoids, however, are not 
uniformly distributed in the retina. The aggregate concentration of both carotenoids is 
greatest in the macular region, hence they are collectively called the macular pigment 
(MP). According to Bone et al. (1988), who measured retinal lutein and zeaxanthin 
concentrations between 0mm and 12.2mm from the foveal center, over 50 percent of the 
retina’s macular carotenoids accumulate within one-degree (« 0.33mm) of the central 
point. Lutein and zeaxanthin have two different concentration gradients. In the fovea, 
the concentration of zeaxanthin exceeds that of lutein at a ratio of about 3:1 (Landrum et 
al., 1999). In contrast, lutein is the dominant carotenoid in the peripheral retina, 
accounting for two-thirds of the total concentration. Edge et al. (1997) suggested that the 
higher concentration of zeaxanthin relative to lutein in the central retina was due to its 
greater antioxidant capacity. Other researchers have noted the obvious correlation 
between the distribution of photoreceptors and the differing concentration gradients of
4
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lutein and zeaxanthin (Eisner et al., 1998; Sommerburg et al., 1999). Although both of 
these hypotheses may be correct, they cannot completely account for the high degree of 
variance in MP among individuals.
In the last fifteen years, more than thirty investigations have reported the mean 
macular pigment optical density (MPOD) of various cohorts. The diverse assessment 
techniques and stimulus parameters make meta-analytical estimates o f a population 
average difficult. However, for twelve studies that employed similar assessment 
methods, the mean MPOD (at 30 minutes of retinal eccentricity) of approximately 1,200 
total subjects ranged between about 0.20 and 0.45. Data tables listed in two of these 
studies showed that MPOD ranged between 0.01 and 0.5 in one study (Cuilla et al., 
2001b), and 0.0 and 0.94 in the other study (Hammond et al., 1997b). Despite the 
unknown sources of variance, Hammond and his colleagues, in a series of studies, 
discovered three factors that may contribute to between-subject variability. One, the 
greater light transmission of blue and gray irises, compared to dark irises, may represent 
increased photodegradation of retinal lutein and zeaxanthin, in that individuals with light- 
colored irises tend to have lower MPOD than individuals with dark irises (Hammond et 
al., 1996b). In their study, the mean MPOD for 38 individuals with blue or gray irises 
was 0.25, whereas the mean MPOD of 31 subjects with brown or black irises was 0.38 (p 
< 0.01). Similar findings were observed in recent large-scale studies (Hammond & 
Caruso-Avery, 2000; Cuilla et al., 2001a). Two, cigarette smoking may affect MPOD via 
depleting available body stores of lutein and zeaxanthin or by increasing pro-oxidant 
activity in the retina (Hammond et al., 1996c). These researchers found that, on average, 
smokers had approximately half the MPOD of nonsmokers, 0.16 versus 0.34. Three,
5
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males tend to have higher MPOD than females (Hammond et al., 1996a). In that over 75 
percent o f the body’s supply of carotenoids are found in adipose tissue (Olsen, 1984), it 
may be that females’ greater adiposity provides additional binding sites for carotenoids 
(Su et al., 1998), resulting in less available lutein and zeaxanthin. That is, adipose tissue 
may compete with the retina for carotenoids. It follows, then, that both males and 
females with high amounts of adipose tissue might have lower MPOD. To wit, 
Hammond et al., (2002) reported that obese individuals in their sample had significantly 
lower MPOD than individuals with a BMI (body mass index) less than 29. Although 
these factors identified by Hammond and colleagues may impact MPOD, several studies 
have found contrary relationships. For example, in a study by Johnson et al., (2000), 
females had significantly higher MPOD, despite their greater adiposity. In another study 
by Beatty et al., (2001), there was no relationship between MPOD and either smoking 
status or iris color. Nonetheless, it is interesting to note that the factors associated with 
lower MPOD in the Hammond studies are also correlated with greater risk for developing 
AMD.
6
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CHAPTER II
AGE-RELATED MACULAR DEGENERATION
AMD is the leading cause of irreversible legal blindness among the aged 
population in the United States (National Advisory Eye Council, 1998). About twenty- 
percent of the population over the age of 60 have an early form of AMD called age- 
related maculopathy (ARM; Klein et al., 1992; Cruickshanks et al., 1997), and between 
five and eight-percent (six to ten-million Americans) have developed macular 
degeneration (Beatty et al., 1999; la Cour et al., 2002). The hallmark of AMD 
pathophysiology is the accumulation of extracellular debris between the retinal pigment 
epithelium (RPE) and Bruch’s membrane. The extracellular debris, called drusen, 
consists of various cellular materials (e.g., unphagocytized disc membranes) thought to 
be excreted by dysfunctional RPE cells (Hogan, 1972). As extracellular deposits 
accumulate, RPE cells are stretched, depigmented and may eventually die, ultimately 
resulting in photoreceptor necrosis (Young, 1987). Drusen formation occurs with age, 
with most individuals over the age of 50 having drusen in at least one eye (Fine et al., 
2000). A few small (< 64pm), yellow drusen with demarcated borders, so called “hard” 
drusen, are usually asymptomatic and not a strong risk factor for AMD. In the Beaver 
Dam Eye Study, for example, only one individual with exclusively hard drusen 
developed AMD (Klein et al., 1997). In contrast, “soft” drusen are large (> 64pm), pale 
yellow, have poorly defined boundaries, and are a potential risk factor for AMD (Zarbin, 
1998). When the number or size of drusen significantly impair central vision, often a
7
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visual acuity o f 20/200 or worse, the individual is said to have atrophic (dry) AMD. In 
15% of individuals with dry AMD, a more devastating loss of vision occurs when new 
choroidal blood vessels grow and penetrate the weakened Bruch’s membrane (Goldsmith, 
2003). These fragile blood vessels often hemorrhage, resulting in extensive 
photoreceptor death. This latter form of AMD is called “wet” or exudative AMD.
A number of risk factors for ARM and AMD have been identified in recent 
studies. In addition to genetic susceptibility (Zarbin, 1998) and age (Beatty et la., 2001), 
some potential risk factors for AMD include: light-colored irises (Sandberg et al., 1994; 
Pratt, 1999), light exposure (Young, 1988; van der Hagen et al., 1993), female sex 
(Cruickshanks et al., 1993; la Cour et al., 2002), BMI (Schaumberg et al., 2001) and 
cigarette smoking (Seddon et al., 1996; Evans, 2001). Another important factor that 
receives a great deal of attention is diet. Several studies have found positive correlations 
between AMD and fat consumption (Cho et al., 2001), and inverse correlations between 
macular insult and carotenoid intake (Snodderly, 1995; Mares-Perlman et al., 2001). For 
example, Snellen et al. (2002) showed that the prevalence of AMD was almost twice as 
high in individuals who consumed a low-lutein diet, compared to individuals with a lutein 
rich diet. Given the similarity between the factors correlated with low MPOD and the 
risk factors associated with AMD, as well as the possible inverse relationship between 
dietary carotenoid intake and macular damage, numerous researchers have postulated that 
the MP may protect the retina.
8
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CHAPTER III
PROTECTIVE ROLE OF MACULAR PIGMENT
The macular carotenoids may protect the retina and contiguous tissues via the 
same mechanisms observed in plant systems. One such way in which retinal lutein and 
zeaxanthin may afford protection is via their ability to quench free radicals. Free radicals 
are highly unstable molecules due to an unpaired electron in their outermost orbit. To 
become stable, free radicals must capture an electron from another molecule, in turn, 
producing another unstable molecule. This initial process can trigger a chain of such 
reactions, as unstable molecules steal electrons from adjacent molecules—the outcome 
often being damage to the involved particles. Several oxidation products of lutein and 
zeaxanthin were discovered in donor retinae by Khachik et al. (1997), suggesting that the 
macular carotenoids may interact and possibly quench free radicals in the retina.
Free radicals are generated throughout the body, but the presence of high oxygen 
content and focused SW light make the posterior ocular tissues particularly prone to the 
generation of these reactive species. For example, lipofuscin, the metabolic byproducts 
that accumulate in RPE cells with age, are photogenerators of oxygen radicals (Gaillard 
et al., 1995; Bonnel et al., 2003), perhaps the most deleterious free radical species (van 
der Hagen et al., 1993). Oxygenated radicals, such as hydroxyl radicals and hydrogen 
peroxide species, are often used in in vitro analyses to estimate carotenoids’ antioxidant 
efficacy. In short, researchers can determine a carotenoid’s relative antioxidant capacity
9
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by measuring the amount of light energy passing through a solution containing free 
radicals and a specific carotenoid. As carotenoids bind with free radicals and share 
electrons, they are degraded, resulting in less available pigment to absorb light. 
Consequently, more light energy passes through the solution. For example, Woodall et 
al. (1997b) found that in a solution containing peroxyl radicals, there was about a thirty- 
percent increase in both zeaxanthin’s and lutein’s transmittance at A.max after ten minutes 
of incubation. In other words, almost thirty percent of lutein and zeaxanthin 
concentrations were degraded in ten minutes. In a solution containing hydrogen 
peroxide, these same researchers found that after five minutes, a little over thirty percent 
of the total lutein concentration was degraded, and almost sixty-five percent of the 
zeaxanthin concentration was depleted. This suggests that in the presence of hydrogen 
peroxide, zeaxanthin may be a more effective antioxidant than lutein. Compared to other 
carotenoids like P-carotene and lycopene, lutein and zeaxanthin have much slower 
degradation rates in the presence of free radicals (Mortensen & Skibsted, 1997a; 1997b; 
Woodall et al., 1997a), suggesting that they are less effective antioxidants. In turn, the 
rapid free radical degradation or photo-bleaching of other carotenoids (e.g., lycopene) 
might be the basis for their absence in the retina (Siems et al., 1999). However, other 
carotenoids, like astaxanthin are more photo-stable than lutein and zeaxanthin, but less 
effective as antioxidants. It seems, then, that lutein and zeaxanthin’s presence in the 
retina represents an evolutionary compromise between antioxidant effectiveness and 
photo-stability.
A second way in which MP may protect the retina is via screening SW light. The 
absorption spectrum of MP resembles a mesokurtic bell-curve, ranging between 410nm
10
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and 520nm, with a maximum 
absorption at 460nm (see Figure 
1; Wyszecki and Stiles, 1982). 
Interestingly, MP absorbs light 
at the more damaging end of the 
visible spectrum. Ham et al. 
(1976) measured retinal damage 
as a function of intensity and 
wavelength, and found that 
approximately hundred times 
less energy is needed at shorter 
wavelengths (e.g., 440nm) to produce retinal insult, compared to longer ones (e.g., 
590nm). The elevated damage potential of SW light has also been noted by other 
investigators (Ruffolo et al., 1984). The link between MP’s absorption spectrum and the 
greater ability of SW light to cause damage seems obvious; MP may absorb potentially 
harmful SW energy and dissipate it as heat, attenuating the amount of light energy 
reaching the photoreceptors and supportive tissues. Thus, the combined functionality of 
retinal lutein and zeaxanthin—a SW filter and antioxidant—may protect the macula from 
light-induced insult (Snodderly, 1995; Pratt, 1999), and thereby sustain visual sensitivity 
(Hammond et al., 1998).
In addition to protecting the retina against light damage, the filtration effects of 
MP may help to improve visual acuity. Wooten and Hammond (2002) referred to this 
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Figure 1: Absorption spectrum o f macular pigment 
measured psychophysically by Wyszecki and Stiles 
(1982).
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cornea) inherently produce longitudinal chromatic aberration, such that an emmotropic 
eye focused on a middle-wavelength (MW) target will bring SW light to a focus anterior 
to the retina (myopic), and long-wavelength (LW) light to a focus posterior to the retina 
(hyperopic). This effect is most pronounced for SW light, exceeding -1.0 diopters for 
wavelengths below 470nm (Wyszecki & Stiles, 1982). The consequences of chromatic 
aberration on normal viewing conditions are often unnoticed, if  not compensated for by 
the visual system (i.e., down-regulating the response of the short-wave system). Only 
under experimental conditions are the effects o f chromatic aberration apparent. For 
example, subjects report the presence of a “violet” penumbra when viewing a broad-band 
target (Hammond et al., 2001). Perhaps the perceptual intensity o f this SW fringe is 
attenuated by the MP. Indeed, Reading and Weale (1974) calculated that the filtration of 
SW light by MP should lessen the appearance of chromatic distortion. Although there is 
little empirical evidence to suggest that MP may improve acuity via attenuating 
chromatic aberration, several studies have reported increased visual function in 
individuals with macular disease after intervention with spinach (Richer, 1999) and lutein 
supplements (Dagnelie et al., 2000; Olmedilla et al., 2001). .
The SW light filtration of MP may also impact other conditions involving light 
exposure. For example, Mesri and Dellepiane (1991) investigated the ability of various 
filters to mitigate the photoconvulsive response in patients with photosensitive epilepsy. 
They found that SW absorbing filters could lessen or eliminate photoconvulsive 
responses, whereas filters had little effect. Perhaps the filtering properties of MP could 
impact patients’ thresholds for photoconvulsive responses, such that increased MPOD 
could improve the quality of life for individuals with photosensitive epilepsy.
12
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CHAPTER IV
PHOTOPHOBIA
MP may also influence the magnitude of discomfort associated with photophobia 
(PP)—a condition characterized by the exacerbation or generation of pain or discomfort 
as a consequence of normal light exposure. Although all individuals have likely 
experienced an acute episode of PP, or dazzling glare (Vos, 2003), as they entered a 
bright environment after prolonged exposure to dark surroundings (e.g., exiting a movie 
theater on a sunny day), some individuals suffer from chronic light-induced pain. For 
example, patients with neurological disorders, such as trigeminal neuralgia (Wolff, 1963), 
and individuals suffering from eye diseases, like conjunctivitis, retinitis pigmentosa, and 
AMD (Lebensohn, 1934; 1951; Gawande et al., 1989; Bacotti, 2001), often report 
persistent hyper-sensitivity to light and periods of PP as symptoms of their condition. PP 
also appears to accompany migraine headaches (Drummond, 1997; Vanagaite-Vingen & 
Stovner, 1998; Muelleners et al., 2001), and maybe more common among females 
(Krymchantowski & Moreira, 2001). It should be noted that PP is a clinical term, lacking 
a standardized operational definition, and is sometimes referred to as photoaversion or 
discomfort glare in non-clinical literature.
The etiology of visual pain associated with extreme light exposure (e.g., snow 
blindness) is usually the result of UV light induced damage to the corneal epithelium. 
Under normal light exposure, however, the mechanisms mediating visual discomfort or 
pain are poorly understood. Research in the early 1900s demonstrated that several
13
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functioning anatomical structures were necessary to experience PP. Although the retina 
is insensible to pain, it seems logical that the photoreceptors play a role in PP. Siegwart 
(1920) showed that only wavelengths of light within the visible spectrum could produce 
PP. Further, he showed that individuals with bilateral blindness could not experience 
visual discomfort in response to light. In three individuals with unilateral blindness, iris 
constriction and pain was reported in the blind eye when the functioning eye was exposed 
to light (Siegwart, 1920). Other investigators also demonstrated that iris constriction was 
involved in PP. For example, in one study, pharmacological dilation of subjects’ pupils 
alleviated the visual discomfort they previously experienced when entering sunlight 
(Nagel, 1901). These findings suggest the neural pathway responsible for (bilateral) iris 
constriction may be necessary to experience visual discomfort; in particular, the optic 
tract projecting to the Edinger-Westphal nuclei in the pretectal midbrain, and the inferior 
division of the oculomotor nerve (3rd cranial nerve), which connects these nuclei with the 
iris sphincter. After noting that the iris dilates and constricts with some rate of recurrence 
when the eye is exposed to bright light (i.e., hippus), Hopkinson (1956) suggested that 
oscillations o f the iris might be involved in visual discomfort. Although research by 
Howarth and colleagues (1972) failed to corroborate this possibility, an intact trigeminal 
nerve (5th cranial nerve), connecting to the ciliary body and the iris dilator muscle via the 
nasociliary and long ciliary nerves, is necessary to experience PP (Lebenson, 1951). 
Recently, Stringham et al. (manuscript submitted for publication) conducted a series of 
experiments revealing that small bistratified and parasol ganglion cells may mediate PP. 
Small bistratified ganglion cells are thought to contribute to the blue-yellow opponent 
processes, and give rise to the koniocellular pathway (Kremers et al., 2001). Parasol cells
14
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give rise to the magnocellular visual pathway, which is involved in processing depth, 
movement and is characterized by a luminosity function (Kaplan & Shapley, 1986; 
Livingstone & Hubei, 1987). Interestingly, some parasol ganglion cells project to 
pretectal nuclei (Rodieck, 1998), perhaps contributing to iris constriction.
Few studies have investigated the stimulus parameters mediating PP. Instead, 
most research has focused on a similar phenomenon called discomfort glare—a condition 
in which distracting, possibly discomforting, light sources are located in the peripheral 
field of view (Vos, 2003). Most research investigating the stimulus parameters necessary 
to elicit discomfort glare (or PP) in normal observers has relied on subject self-report. 
Typically, subjects are asked to rate their visual discomfort in response to a stimulus 
using the standardized de Boer scale (de Boer, 1967), which ranges from 1 (unbearable) 
to 9 (just noticeable). Using this scale, Sivak et al. (1999) found that both the intensity 
and duration of a light source significantly affected observers’ ratings of discomfort. As 
the duration or intensity of the light source increased, so did the apparent level of visual 
discomfort. Other investigators have reported that discomfort thresholds are lower for 
binocular targets (Vanagaite et al., 1997; Vanagaite-Vingen & Stovner, 1998), suggesting 
that visual discomfort may involve binocular summation. Waters et al. (1995) 
demonstrated that nonuniform stimuli (i.e., gratings) presented in the peripheral retina 
were less discomforting than nonuniform stimuli viewed centrally.
In 1994, Berman et al. introduced the use of electromyography for assessing 
discomfort glare. They placed electrodes around the eye and measured muscle 
contraction in response to light exposure. This “objective” measure of visual discomfort 
is based on the premise that a discomforting light will trigger a contraction of the
15
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orbicularis muscle, resulting in a reduction of the palpebral fissure (i.e., a squint). For a 
glare source located at 11 degrees retinal eccentricity, they found that muscle contraction 
increased as the luminance of the light source increased. Further, their subjects appeared 
to experience more discomfort when viewing a 2-degree glare source, compared to a 1- 
degree source. In a subsequent study, Berman and colleagues (1996) used this same 
objective technique to measure the effects of a light’s spectral emmitance on discomfort. 
They found that a light source with more energy in the LW end of the spectrum induced 
greater muscle contraction (i.e., discomfort) compared to a light source with more energy 
at shorter wavebands. A greater discomfort in response to LW light was also noted by 
Main et al. (2000). According to their research, the discomfort thresholds for both LW 
and SW light targets are lower than for MW and broad-band targets. Similarly, Kuller 
and Wetterberg’s (1993) subjects reported that full-spectrum fluorescent lights 
(correlated color temperature > 5000 K) were more discomforting than warm-white 
fluorescent lights (correlated color temperature = 3000 K). In a recent, more 
experimentally rigorous investigation, Stringham et al. (2003) looked at the effects of 
individual wavelengths on the threshold for PP. Unlike other researchers, they controlled 
retinal illuminace (pupil size) by using Maxwellian view optics. Their procedure 
involved focusing monochromatic targets, subtending 5 degrees o f arc and presented for 
5 seconds, on the fovea of three normal observers. The method of limits was used to 
determine the energy necessary to elicit a criterion squinting response as measured by 
electromyography at wavelengths between 440nm and 640nm. The normalized action 
spectra of PP for all three of the observers showed a high degree of between- and within- 
subject uniformity. Figure 2 shows the normalized action spectra for two subjects. As
16
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Figure 2: Photophobia action spectra for two subjects 
from Stringham et al (2003). The two action spectra 
for each subject are normalized at peak sensitivity.
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Figure 3: Mean photophobia action spectra for two 
subjects in Stringham et al’s (2003) study, corrected 
for lens and macular pigment optical density. For 
comparison, the functions are plotted with the retinal 
damage function measured by Flam et al (1976).
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one can see, for wavelengths 
between 520nm and 640nm, there 
was a positive trend between 
wavelength and the energy needed 
to produce PP. That is, less energy 
was needed to induce a squint at 
520nm compared to 640nm. At 
shorter wavelengths the spectra 
appear as a notch centered at 
460nm. Interestingly, the trough 
and shape of this notch roughly 
resemble the log transmittance 
spectrum of MP. In fact, the 
difference in MPOD between the 
two subjects seems to account for 
their slight, but uniform, difference 
in photophobic sensitivity below 
520nm. Further, when the filtering 
effects of MP, as well as the lens, 
are accounted for, the notch 
disappears, and the PP spectra 
resemble the retinal damage 
function reported by Ham et al.
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(1976; see figure 3). These findings suggest that MP may attenuate PP or discomfort 
associated with sufficiently intense SW targets and may impact the threshold for PP 
under normal viewing conditions.
18
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CHAPTER V
RESEARCH OBJECTIVES
The objective of the present project was to test directly the relationship between 
MP and PP. First, it is hypothesized that these two phenomena are positively correlated 
such that individuals with higher MPOD will require more energy to experience PP when 
viewing a SW target relative to a LW target. Second, in an attempt to establish a causal 
relationship, it is hypothesized that augmenting MPOD via lutein supplementation will 
result in corresponding increases in the threshold for PP for a SW target relative to a LW 
target. If this is the case, increasing MPOD, either through diet or supplementation, may 
represent a viable treatment for some individuals who suffer from frequent episodes of 
PP.
19
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CHAPTER VI
METHODS
Measurement o f Macular Pigment Optical Density
The recent interest in MP’s role in the development of AMD has prompted many 
researchers to devise methods for measuring retinal lutein and zeaxanthin concentrations 
in vivo. These techniques take advantage of the absorption spectrum and retinal 
concentration gradient of MP; specifically, the filtration of SW light by the MP in the 
fovea relative to the parafovea. For example, in fundus photographic techniques (e.g., 
Kilbride et al., 1989; Abadi and Cox, 1992), two images of a bleached retina are 
obtained, one using light absorbed by MP and another using light not absorbed by MP.
In the former photograph, the MP will appear dark to black. The two photographs are 
digitized, rendered in grayscale, then aligned using ocular landmarks. MPOD is obtained 
by subtracting the density differences (grayness) at each pixel between the two 
photographs. In another technique, a reflection spectrum of the retina is obtained using a 
scanning laser ophthalmoscope (e.g., Berendschot et al., 2000; Wiistemeyer et al., 2003). 
This instrument measures the amount of monochromatic light reflected from various 
retinal loci. To calculate MPOD, the amount of (reflected) energy recorded by a 
photodetector when the laser falls outside the fovea is compared to the energy when the 
laser falls on loci in the fovea. Two additional techniques also measure MPOD using 
reflectometric methods. Bernstein et al. (2002) and Gellerman et al. (2002) measured 
MPOD by exposing the fovea and parafovea to an argon laser and measuring the distinct
20
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Raman signals of lutein and zeaxanthin. Another innovative technique involves 
measuring the amount of lipofuscin fluorescence in the fovea and parafovea after 
exposure to SW and MW monochromatic light (e.g., Delori et al., 2G01). Unfortunately, 
all of the aforementioned techniques require pupillary dilation with mydriatics, and 
consequently, a lengthy time investment from the subject.
One of the quicker and easier techniques to measure MP, and hence the most 
popular, involves measuring the effects of MP on spectral sensitivity using a 
psychophysical technique called heterochromatic flicker photometry (HFP). Like other 
in vivo measures, this technique takes advantage of the absorption spectrum and retinal 
concentration gradient of MP; specifically, the filtration of SW light by the MP in the 
fovea relative to the parafovea. Because the MP absorbs some SW light before it reaches 
the photopigments, an estimate of MPOD can be obtained by comparing the spectral 
sensitivity of retinal loci screened by MP with loci where lutein and zeaxanthin do not 
accumulate. This possibility, however, is predicated on these two retinal loci having 
identical spectral sensitivities, save the intervention of MP.
The concentration of MP declines exponentially with increasing eccentricity, such 
that less than 5 percent of the total lutein and zeaxanthin in the retina accumulates beyond 
1.6mm (« 5 degrees). Consequently, retinal loci five degrees outside the foveal center 
can be used to obtain a spectral sensitivity relatively unaffected by MP. To compare 
spectral sensitivities between the foveola and say, a locus 7 degrees outside the fovea, the 
testing conditions must favor the input of MW and LW cones while eliminating or 
diminishing the input of SW cones and rods. These actions are necessary because only 
MW and LW cones remain in relatively equal proportion to one another from the foveola
21
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to 7 degrees eccentricity (Cicerone & Nerger, 1989; Nerger & Cicerone, 1992). The 
distribution of rods and SW cones, on the other hand, changes dramatically across the 
macula (0sterberg, 1935; Curcio et al., 1991). One way to diminish the involvement of 
rods and SW cones in spectral sensitivity measures is to conduct the test using 
background light that is more strongly absorbed by these receptor types than by MW and 
LW cones. A background composed of SW light renders the SW cones and rods 
insensitive to the lights used to measure MPOD. The importance of conducting the test 
on a SW background is illustrated in figure 4. As one can see, measures of MPOD are 
relatively unaffected by a broad range of background intensities provided they exceed 
about 2 log Td, but a barely perceptible background, or no background, results in
profound overestimations of MPOD 
owing to the intrusion of SW cones 
and rods. Additionally, using a 
flickering stimulus that alternates at a 
frequency above the SW-cone fusion 
threshold can eliminate the 
contribution of SW cones.
The stimulus used to measure 
MPOD with HFP consists of a small 
flickering disc superimposed on a 
large, SW background. The flickering 
disc is composed of two 
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Figure 4: Mean macular pigment optical density 
(MPOD) as a function o f background intensity. The 
function represents a mean o f six sessions for one 
subject (AW). MPOD was measured in free view at 
30' eccentricity using the Macular Metrics optical 
system. The flicker frequency o f the target was not 
adjusted during an experimental session.
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Fixation Point 6 degree, 470nm 
Background
1 degree, 460 /  570nn 
Test Stimulus
square-wave counter phase between a reference light and a test light (see figure 5). The
radiance and wavelength 
composition of the reference 
light remain invariant, while 
the test light’s radiance and 
wavelength composition are 
manipulated. To measure 
MPOD, it is necessary to 
use a reference light 
composed of a wavelength 
outside the absorption 
spectrum of MP. The 
chromatic composition of 
the test light is varied, 
allowing MPOD estimates
Square-wave counterphase presentation of test stimulus
S t  I «  M R SB m j  m f  S B  |
Temporal Frequency 8-12 Hz
Figure 5: Schematic o f the stimulus used to measure macular 
pigment optical density with heterochromatic flicker photometry. 
Below the schematic is a graphical representation o f the counter­
phase presentation o f the test stimulus.
at different wavelengths. For each test wavelength, the subject adjusts the radiance of the 
test light until the test stimulus appears to stop flickering—a condition referred to as 
sensation luminance (Kaiser, 1988). Measuring the energy necessary for a subject to 
achieve sensation luminance at various wavelengths yields a spectral sensitivity curve.
By obtaining two such spectral sensitivity curves, one in the fovea and another in the 
parafovea, researchers can determine the effect of MP on spectral sensitivity by 
normalizing the two functions (see figure 6). A measurement of MPOD can be 
calculated by taking the log ratio of these two functions. That is, for each test
23
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Figure 6: Foveal and parafoveal spectral sensitivity 
functions measured using heterochromatic flicker 
photometry. The data are normalized at 560nm. 
The log ratio o f  the two functions is attributable to 
absorption by macular pigment.
wavelength, the log energy 
necessary to achieve sensation 
luminance in the fovea minus the 
log energy needed in the parafovea 
yields a measure of MPOD. MP 
absorption spectra obtained using 
this psychophysical technique are 
analogous to those obtained via 
other methods, such as 
spectrophotometry (Bone et al., 
1985), microdensitometry 
(Snodderly et al., 1984), and fundus 
reflectometry (Kilbride et al.,
1989). To obtain a MP absorption spectrum with HFP requires a lengthy time investment 
from the subject. As a result, most researchers simply measure MPOD at 460nm, as this 
is the wavelength of peak absorption. Cautious researchers also occasionally measure 
MPOD at 490nm as a validity check for a subject’s 460nm measure. Measurements 
using a 490nm test light should yield MPOD approximately half the value obtained using 
a 460nm test light (Wyszecki & Stiles, 1982).
In 1987, Wemer et al. measured MPOD after manipulating several parameters of 
the HFP task. Of particular interest was their finding that MPOD was predicated on the 
radius of the foveal test stimulus, or more appropriately, its visual angle. They found that 
as the visual angle of a centrally fixated test stimulus increased, MPOD decreased
24
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exponentially. The relationship between the radius of the test stimulus and MPOD 
corresponded well with the retinal concentration gradient of MP established with HPLC. 
This finding suggests that MPOD is predicated on the effects of MP absorption at the 
edge of a flickering test stimulus. For example, the edge of a centrally fixated one-degree 
test disc will extend to 0.5 degrees eccentricity, and will yield a measure of sensation 
luminance affected by MP absorption at this retinal locus. The fact that sensation 
luminance is dependent on MP absorption at the edge of a flickering disc target, and not 
on space-averaged MPOD, is further supported by the observation that a one-degree 
annulus yields the same
measure of sensation 
luminance as a one-degree test 
disc.
In the current 
experiment, MPOD was 
measured at 460nm using four 
centrally fixated targets—40- 
minute disc (0.66 degrees), 1- 
degree disc, 2-degree annulus, 
4-degree annulus—and a 
parafoveal reference target (2 
degree disc) centered at 7 
degrees of eccentricity, 
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Figure 7: Schematic o f the retinal loci and corresponding 
macular pigment optical density profile assessed using the 
Macular Metrics densitometer. Stimuli A and B are centrally 
fixated discs that subtend 40' and 60' o f  visual angle, 
respectively. Stimuli C and D are centrally fixated annuli, 
with outer edges subtending 120' and 240', respectively. The 
widths o f  the annuli subtend 20' o f visual angle. Stimulus E is 
a 120' disc centered at seven degrees eccentricity by the 
subject's fixating a small point o f  light to the left o f  the 
stimulus.
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between 20-minutes and 2-degrees eccentricity (see figure 7). The test stimuli were 
presented in free-view using an optical system recently developed by the Macular Metrics 
Corporation ® (Rehoboth, MA; see Wooten et al., 1999). This system produces the test 
stimuli with an arrangement of 4 LEDS—two with a peak wavelength at 458nm, one 
with a peak at 490nm, and the fourth with a peak at 530nm. The 530nm LED (1.7 log 
Td) is electronically driven to alternate in square-wave with either the two 458nm LEDs, 
for estimates of MPOD at its wavelength of peak absorption, or the one 490nm LED for 
density estimates at this test wavelength. Light from these LEDs is collimated by a 
planoconvex lens and defined by one of five apertures constructed of Mylar film.
Another LED arrangement, comprised of 4 LEDS with a peak spectral emmitance at 
470nm is used to produce the background (1.5 log Td). Light from this arrangement 
passes through a planoconvex lens and is defined by a 6-degree aperture. Finally, light 
from both LED arrangements is combined using a beam-splitter. When the subject’s 
right eye is properly aligned with the optical axis of the beam splitter, the stimulus 
appears as a flickering test disc (or annulus) superimposed on a large, SW background 
(figure 5). At the center of the flickering test stimulus is a small, 5-minutes of arc, 
fixation point. For the four foveal measures of sensation luminance, the subject fixates 
this small point as he or she adjusts the intensity of the test LED(s) until flicker is 
minimized or eliminated. To perform the reference parafoveal measure, the subject 
fixates a small, LW LED approximately 7 degrees of visual angle from the center of a 
two-degree test stimulus (disc). This fixation point is located to the left of the test image, 
resulting in a nasal reference measure of sensation luminance. The subject’s task,
26
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however, is identical to the foveal task: to adjust the energy of the test LED(s) until the 
test stimulus appears stable (i.e., stops flickering).
The ability to stabilize the flickering test stimulus is highly dependent on the 
flicker frequency of the target, especially in the fovea. If the flicker frequency is too low, 
the subject will likely be unable to eliminate the apparent flicker o f the test target. On the 
other hand, if the flicker frequency is too high, the test stimulus will appear stable for a 
broad range of energy (i.e., radiance) supplied to the LED(s). Ideally, the subject should 
be able to adjust the intensity of the test LED(s) to observe a “zone” of flicker on both 
sides of a small null zone—range of radiances for which the test stimulus appears not to
flicker. The subject’s specific task 
is to find this null zone and then 
estimate its mid point. Typically, a 
subject’s estimate of the mid point 
for a particular stimulus varies 
slightly between and within testing 
sessions. One method to reduce 
such variability is to adjust the 
flicker frequency of the test 
stimulus until the null zone is 
rather small. In general, the null 
zone and flicker frequency are 
related positively, such that 
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Figure 8: Relationship between flicker frequency o f the 
test stimulus and size of the null zone in HFP for one 
subject (JMS). The data represent the mean o f two 
sessions and were measured in Maxwellian view with 
a centrally fixated 40' target. The spectral composition 
of the test lights was the same as those used in the 
current experiment. Above 19Hz, the size o f the no­
flicker zone increased with increasing flicker 
frequency. Below 18Hz, the subject could not 
eliminate flicker.
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tends to increase the null zone. The relationship between flicker frequency and null zone 
size is illustrated in figure 8. In the current project, the flicker frequency of each target 
was adjusted until the subject perceived a null zone that spanned approximately 100 
radiance units according to the Macular Metrics’ photometer readout. A null zone of this 
size is small enough to limit subject variability, but large enough so that subjects can 
easily and consistently perform estimations of the null zone’s mid point. Regardless of 
the size of the null zone, subjects rarely select the exact same mid-point on successive 
attempts. In order to reduce the effects of such variability, multiple measures are 
obtained. In fact, data reported by Werner et al. (1987) suggest that the flicker frequency 
of the target has little effect on calculations of MPOD when several mid-point 
estimations are obtained for each target. Eight mid-point estimations were obtained for 
each test stimulus in the current project. The mean radiance of these eight measures was 
used to calculate MPOD at each eccentricity.
Measurement o f Photophobia
Previous researchers investigating the stimulus conditions necessary to induce 
visual discomfort have failed to control the amount of light entering the eye. Only 
Stringham et al. (2003) controlled retinal illuminance by presenting their stimuli in 
Maxwellian view. In this technique, light is focused at the plane of the pupil to a beam 
narrower than the smallest aperture achievable by the iris, thereby obviating the effects of 
pupil size on retinal illuminance. This same technique was used in the current 
experiment. In short, a three-channel Maxwellian view optical system was used to 
produce the PP test stimuli. One channel was used to produce an 8.2-degree, broadband 
test stimulus. Light in this channel passed through either a SW broadband filter (Oriel
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Corp. #59830) or a MW- to LW 
filter (Tiffen #15). The 
transmission spectra of these two 
filters are presented in figure 9. As 
one can see, the SW broadband 
filter transmits light strongly 
absorbed by the MP, whereas the 
light transmitted by the MW- to 
LW filter is outside the absorption 
spectrum of MP. Another channel 
was used to create a mesopic (-1 
log cd/m ), broadband, 30.5-degree 
background. The third channel 
produced a small, 20 minutes of arc, LW fixation light. A schematic of the PP test 
stimulus is depicted in figure 10. Neutral density filters were used to control the energy 
in each channel.
At the beginning of each experimental session, the subject’s right pupil was 
aligned with the optical axis of the system using a reticle. Throughout the experiment a 
dental impression and forehead rests were used by the subject to maintain this position. 
After the alignment procedure, subjects dark adapted for 20 minutes. Subjects then 
fixated the small LW light for two minutes. This fixation light was located either 
centrally, for foveal measures of PP, or at 10.1 degrees temporal eccentricity for 
parafoveal measures of PP. After the subject adapted to the background for two minutes,
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Figure 9: Transmission spectra for the two filters 
used to produce the stimuli for measures of 
photophobia thresholds. The light passing through 
the “blue” broadband filter falls within the 
absorption spectrum o f macular pigment (MP). In 
contrast, the MP does not absorb any apppreciable 
wavelengths o f light passing through the “orange” 
broadband filter.
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the experimenter announced that the PP stimulus was to be presented. The time between 
the experimenter’s cue and the presentation of the test target was quasi-random, between
5 and 20 seconds. After 
the five-second 
presentation of the test 
target, subjects rated 
their level of visual 
discomfort using a 10- 
point psychophysical 
scale, where a 1 
represented no 
discomfort and a 10 
represented PP—i.e., the 
light caused sufficient 
discomfort to elicit a 
squint and subjects 
wanted to divert their
eye from the target. The initial test target was well below the subject’s PP threshold. By 
use of the method of ascending limits, the energy of the test light was increased by 
subtracting neutral density from channel one. If the subjects rated their discomfort 
between 5 and 9, 0.1 log units of density was subtracted, otherwise 0.3 log units was 
removed from the channel. Random catch trials were performed to assess subject bias. 







20 minute fixation point at 
10.1 degrees o f  eccentricity
Figure 10: Schematic o f the foveal and parafoveal test stimuli used 
to measure photophobia thresholds. For each retinal loci, the 8.2 
degree test disk was composed o f light passing through either the 
broadband “blue” filter or the broadband “orange” filter (see text).
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of the die was 2, 0.1 log units of density was added to the test channel. If the subject 
correctly rated the stimulus as less intense (i.e., a lower number) than the previous target, 
the response was recorded as a “hit.” Conversely, if the subject incorrectly rated the 
stimulus, rating it as equally or more discomforting than the previous stimulus, it was 
recorded as a “false alarm” (FA). Additional non-random catch trials were also 
performed by the experimenter to better define subjects’ PP thresholds. To maintain the 
same level of retinal sensitivity prior to each presentation of the test stimulus, subjects 
covered their right eye with an eyepatch and dark adapted for fifteen minutes between 
trials. This procedure was repeated until the subject reported that he or she experienced 
PP (i.e., a rating of 10) while viewing the test stimulus. PP thresholds for the 8.2 degree 
test stimulus were measured for the SW (“blue”) target in the fovea and parafovea and for 
the MW- to LW (“orange”) target in the fovea and parafovea. The four test conditions 
are illustrated in figure 11. After the experiment, the energy of the test lights which 
induced PP were measured using a radiometer (United Detector Technology Optomteter 
#61). The energy of the four targets was log transformed, and 0.46 log units was 
subtracted from the log orange energy to correct for the orange filter’s greater energy 
transmission. The corrected log energy of the orange target that induced PP was then 
subtracted from the log energy of the blue target that induced PP to yield a foveal PP 
ratio. A parafoveal PP ratio was calculated in the same manner. Finally, a difference 
ratio (PP ratio) was calculated by subtracting the parafoveal PP ratio from the foveal PP 
ratio. Before the project was initiated, the above procedure was used to compare PP 
thresholds measured with a scaling technique to those determined with electromyography 
(electromyogram—EMG). Most of the studies investigating visual discomfort asked
31
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Fovea Parafovea
Log Energy for 
Photophobia =
2.289
Log Energy for 
Photophobia =
3.107




Log Energy for 
Photophobia =
2.501
Fovea Photophobia Ratio =0.152 Parafovea Photophobia Ratio =-0.606
Difference Ratio (PP Ratio) = 0.758
Figure 11: Schematic o f the four photophobia (PP) test stimuli used to measure PP thresholds.
Stimuli A and B were used to measure foveal PP thresholds for the “orange” and “blue” lights, 
respectively. Stimuli C and D were used to measure parafoveal PP thresholds for the orange and 
blue lights, respectively. The calculation o f PP ratio is illustrated with an example. In the fovea 
and parafovea, the log relative energy necessary to induce PP for the orange stimulus was 
subtracted from the energy necessary to induce PP with the blue stimulus. The absolute difference 
between these two ratios was called the PP ratio.
subjects to use a scale (as was the case in the present study), such as the de Boer scale (de 
Boer, 1967), to quantify their level of discomfort when viewing a light source. As 
mentioned earlier, two groups of researchers, however, attempted to measure PP using an 
“objective” procedure. Both Berman et al. (1994) and Stringham et al. (2003) recorded 
gross muscle potentials around the eye (EMG) while their subjects viewed a light source. 
Essentially, these researchers assumed that a sufficiently bright light will compel a 
subject to squint in order to limit the amount of light entering the eye. When the signal- 
to-noise ratio of the EMG trace (i.e., squint magnitude) exceeded a criterion value, the 
subject was defined operationally to have experienced PP. Berman et al. (1994) and
32
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Stringham et al. (2003) also asked their subjects to rate their level of discomfort using a 
scale. Interestingly, both groups of researchers noted a high degree o f correspondence 
between squint magnitude and the subjects’ subjective rating of discomfort. In fact, 
Stringham et al. showed that the PP action spectrum obtained using EMG looked 
essentially identical to the spectrum based on their subjects’ subjective ratings of lights 
just below the PP threshold. Their subjects used the samelO-point psychophysical scale 
used in the present study, where 1 signified no discomfort and a 10 represented PP.
Figure 12 shows their subjects’ 
action spectra for subjective ratings 
of “9,” which represent extreme 
discomfort, bordering on PP, 
compared to the EMG-determined 
spectra of PP. The similarity 
between the scaling and EMG 
functions suggests that a rating scale 
is a viable option for estimating PP, 
particularly if subjects are well 
trained and PP is well defined.
In the studies by Berman et 
al. and Stringham et al., the high degree of correspondence between the objective (EMG) 
and subjective (scale) values may have been partly due to the fact that the scaling 
procedures were coincident with the EMG recordings. To obviate this possibility, one 
naive subject and one well trained subject had their PP thresholds for the blue and orange
33
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Figure 12: Mean electromyographic and scaling 
photophobia action spectra for two subjects in 
Stringham et al’s (2003) study. The functions are 
normalized at 500nm.
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targets measured in two separate sessions. In one session, PP thresholds were measured 
using the aforementioned techniques (i.e., subjects used a psychophysical scale). In the 
other session, PP thresholds for the same four targets were determined using EMG. 
Three nickel-plated, surface electrodes were used to record gross potentials generated 
during a squint: one electrode was attached below the subject’s right eye (test), another 
on the subject’s right temple (reference), and a third on the back of the subject’s neck 
(ground). The electrodes were connected to a Grass Instruments amplifier (#7P3B), 
which sent the signal to a waveform computer program. As in Stringham et al., PP was 
defined as a signal-to-noise ratio of 4:1 on the EMG trace lasting at least 2.5 seconds. 
The data for both subjects’ sessions are presented in figure 13. The high degree of
similarity between the two














Figure 13: Foveal and parafoveal photophobia ratios 
for two subjects measured with electromyography 
and a scaling technique. The data are not 
normalized.
sessions, particularly JMS’s 
functions, suggests that a scaling 
technique can be reliably used to 
determine PP thresholds. Further, a 
psychophysical scaling procedure 
has two primary advantages over 
EMG for determining PP 
thresholds. It is less invasive for 
the subject; and more importantly, 
EMG can only be used to measure 
squint magnitude (behavior), not 
visual discomfort (PP).
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Experimental Protocol
To adequately investigate the impact of MPOD on PP, two separate experiments 
were performed. The primary goal of the first experiment was to investigate the 
correlation between MPOD and the energy necessary to induce PP for the blue target 
relative to the orange target. Using the aforementioned techniques, MPOD and PP 
thresholds were measured in ten, non-smoking individuals, four males and six females, 
ages 21 to 33.
The primary goal of the second experiment was to measure the effects of 
augmented MPOD on the energy needed to induce PP for the four targets. Four subjects 
from experiment one, two males and two females, ages 24 to 31, took 60mg of 
Xangold™ (Cognis, La Grange, IL) dietary supplements daily for twelve weeks. The 
dosage was equal to approximately 30mg of free lutein per day. During the twelve weeks 
of intervention, subjects continued their regular diet. PP thresholds and MPOD were 
measured at baseline and again after six weeks and twelve weeks of supplementation.
The use of human subjects in this project was approved by the University of New 
Hampshire Institutional Review Board.
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The sample’s mean age, BMI, and MPOD at each eccentricity are presented in
table 1 (see Apendix A). BMI was linearly correlated with MPOD at 60' eccentricity (r =
0.786, n = 10, p = 0.006), although this relationship was largely driven by two outliers.
Age, on the other hand, was not significantly correlated with MPOD at any eccentricity.
The mean MPOD profiles for
males and females are illustrated
in figure 14. Although the
sample mean male MPOD profile
is higher at the three central loci,
and the female sample mean at
120' eccentricity, the differences
were not statistically significant
according to independent sample
t-tests. Likewise, there was no
A-A + ■ -r A A-ee u , i j significance difference in BMI orMPOD did not significantly differ between males and
females at any loci.
age between males and females.
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Figure 14: Mean male (n = 4) and female (n = 6) 
macular pigment optical density (MPOD) profiles.




















0.45 0.650.60 0.70 0.75
Photophobia Ratio
S  0 .02-
0.45 0.50 0.55 0.60 0.65 0.70 0.75 0.80
Figure 15: Relationship between PP ratio and 
MPOD. There was a significantly linear 
relationship between PP ratio and MPOD at 20' (A, 
p = 0.009), 30' (B, p = 0.010), and 60' (C, p = 
0.025) eccentricity. MPOD at 120' (D, p = 0.750) 
eccentricity was not linearly related to PP ratio.
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The ten subjects’ MPOD 
at each eccentricity and PP ratios 
were plotted and fit with a linear 
function. As shown in figure 15 a- 
d, there was a significant linear 
relationship between the subjects’ 
PP ratios and MPOD at 
eccentricities of 20' (r = 0.767, p = 
0.009), 30' (r = 0.760, p = 0.010) 
and 60' (r = 0.694, p = 0.025), and 
a non-significant relationship 
between PP ratio and MPOD at 
120' eccentricity (r = -0.115, p = 
0.750).
In the event that PP 
thresholds for SW lights are 
affected by the aggregate filtration 
of MP in the fovea, an estimate of 
total screening was calculated by 
taking the area under the MPOD 
profile. Each subject’s MPOD 
profile was plotted and fit with a 
Gaussian function, using Origin
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7.0® (Northampton, MA). The area under the MPOD profile was calculated to yield a 
Gaussian integrated MPOD (iGMPOD). Several previous researchers have used the 
Gaussian function to explain the foveal distribution of MP (e.g., Snodderly et al., 2004).
The Gassian function can be 
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Figure 16: Subject AW’s macular pigment optical 
density profiles fit with a Gaussian function (A) and a 
Lorentzian function (B).





where y0 = baseline offset (i.e., 
ordinate value of the curve’s 
asymptote); A = total area under the 
curve from the baseline; Xo = center 
of the peak (i.e., mean); w = width 
of the peak at half height. Figure 
16a shows subject AW’s MPOD 
profile fit with a Gaussian function. 
The Gaussian function appears to 
describe the MPOD profile well, 
with an R2 = 0.994. For the other 
nine subjects, the R2 for the 
Gaussian fit ranged from 0.999 to 
0.817. The iGMPOD and PP ratios
38
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for each subject are plotted in figure 17a. As one can see, there was a strong positive 
relationship between iGMPOD and PP ratio (r = 0.830, n = 10, p = 0.002).
The fovea distribution of 
MP has also been estimated using 
the Lorentzian distribution (e.g.,
Stringham et al., 2003). The 
Lorentzian distribution can be 
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where yo = baseline offset, A = 
total area under the curve from 
the baseline; X0 = center of the 
peak; and w = width of the peak 
at half height. Figure 16b shows 
subject AW’s MPOD profile fit 
with a Lorentzian function. For 
subject AW, the Lorentzian 
distribution appears to “fit” his 
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Figure 17: Relationship between integrated 
macular pigment optical density (iMPOD) and 
photophobia ratio (PP ratio). The top panel (A) 
shows the significant, positive relationship 
between integrated Gaussian MPOD and PP ratio 
(p = 0.002). The bottom panel (B) shows the 
significant linear relationship between integrated 
Lorentzian MPOD and PP ratio (p = 0.008).
the Gaussian distribution, with an R2 of 0.999. Except for two subjects, the Lorentzian 
distribution fit each subject’s MPOD profile slightly better (i.e., higher R2) than did the
39
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Gaussian function. For one subject, the Gaussian distribution fit his MPOD profile 
better, and for another subject, who had virtually no MP, the Gaussian distribution and 
Lorentzian distribution had the same coefficient o f determination (R2 = 0.810). The area 
under the Lorentzian fit of each subject’s MPOD profile was calculated to estimate an 
integrated Lorentzian MPOD (iLMPOD). The relationship between iLMPOD and PP 
ratio is shown in figure 17b. Like iGMPOD, iLMPOD was positively related to PP ratio 
(r = 0.775, n =  10, p = 0.008).
To properly fit each subject’s MPOD profile with the Gaussian and Lorentzian 
functions, it was necessary to estimate their temporal MPOD profile. Previous research 
has demonstrated that MP is distributed symmetrically about the fovea (Hammond et al., 
1997b), such that MPOD at 30' eccentricity in the nasal retina is nearly identical to 
MPOD at 30' in the temporal retina. Consequently, an estimate of MPOD in the temporal 
retina may be obtained by taking the MPOD measured at a corresponding locus in the 
nasal retina. This possibility was tested by measuring a detailed nasal and temporal 
MPOD profile in two subjects. The profiles were measured using the Macular Metrics 
optical system mentioned above, with one modification: additional fixation points were 
added to measure sensation luminance at 150' and 300' eccentricity in the nasal and 
temporal retina, and seven-degrees in the temporal retina. As shown in figure 18a-b, 
there was a high degree of uniformity between the subjects’ nasal and temporal MPOD 
profiles. In fact, for subject JMS, the two profiles match almost perfectly. The iGMPOD 
using both profiles is 41.63 for JMS and 69.89 for AW. When iGMPOD is calculated 
using the nasal profile and an estimated temporal profile (as was done in the calculations 
above), iGMPOD for JMS is 41.75, and for AW, 67.33. The iLMPOD for JMS, using
40
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both the nasal and temporal profiles, was 60.27, and for subject AW, 103.28. Calculating 
iLMPOD using the nasal profile and an estimated temporal profile yielded an integrated
area of 60.54 for JMS, and 99.43 for 
AW. Thus, using the nasal profile to 
estimate MPOD in the temporal 
retina resulted in a mean 
underestimation of integrated area of 
less than two-percent. Estimates of 
the MPOD peak derived using the 
Gaussian or Lorentzian functions 
differed less than one-percent 
between the values obtained using 
both profiles and the values obtained 
using the nasal profile and an 
estimated temporal profile. These 
results suggest that a Gaussian or 
Lorentzian integrated MPOD and 
peak optical density can be estimated 
accurately by measuring MPOD in 
the nasal retina and using these 
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Figure 18: Nasal and temporal macular pigment 
optical density (MPOD) profiles for subjects JMS 
(A) and AW (B). The profiles are normalized at 
420' eccentricity.
41
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Experiment Two
The four subjects’ MPOD profiles at baseline and after six and twelve weeks of 
lutein intervention are depicted in figure 19a-d. The group’s mean MPOD profile at 
baseline, visit two and visit three is shown in figure 20. The figure shows that mean 
MPOD increased slightly at the central three loci after six weeks of intervention by the 
consumption of approximately l,260mg of lutein (30mg per day). After an additional six 
weeks of lutein intervention, mean MPOD increased another 0.04 log units at the two 
central loci and about 0.02 log units at the other two loci. According to a randomized
0.3-
Eco8  0.3- <0
-3-
Ooa.5
0 50 100 150 200 250 300 350 400 450
Nasal Retinal Eccentricity (minutes)
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Figure 19: Macular pigment optical density profiles for the four subjects in Experiment 
Two at baseline and after six-weeks (visit 2) and twelve-weeks (visit 3) o f  lutein 
intervention. The MPOD profiles are normalized at 420' eccentricity. Panels A, B, C, 
and D show the MPOD profiles for subjects JPS, LS, AW and MW, respectively.
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block design (RB-3; Kirk, 1995; 
pages 251-286), MPOD 
significantly increased from 
baseline at 20' (F2,6 = 17.35, p = 
0.003, ©2 = 0.73), 30' (F2>6 = 
77.00, p < 0.001, co2 = 0.92) and 
60' (F2j6 = 7.04, p = 0.026, co2 -  
0.50). The changes in MPOD at 
these three loci after six and 
twelve weeks of lutein 
intervention can be described by a 
linear trend (20': F = 26.04, p = 
0.014, co2 = 0.89; 30': F = 495.70, 
p < 0.001, 0)z = 0.93; 60': F = 11.29, p = 0.043, a/' = 0.74), according to analyses using 
orthogonal polynomial contrasts. Changes in MPOD did not depart from linearity.
An integrated MPOD was calculated for each subject’s three MPOD profiles 
using the aforementioned Gaussian and Lorentzian distributions. The Lorentzian
distribution fit the data slightly better than did the Gaussian function for three of the four
2 2 
subjects, using R as a measure of “goodness of fit.” For the Gaussian f i t , R ranged
from 0.999 to 0.950, and for the Lorentzian fit, it ranged from 0.999 to 0.984. Mean
iGMPOD increased from 50.86 (SD = 18.30) at baseline to 56.10 (SD = 17.88) after six
weeks of intervention, and to 60.27 (SD = 19.48) after twelve weeks. Mean iLMPOD
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Figure 20: Mean macular pigment optical density 
profiles for the subjects in Experiment Two at baseline 
and after six-weeks (visit 2) and twelve-weeks (visit 3) 
o f lutein intervention. According to a subjects-by-trials 
analysis, MPOD significantly increased from baseline at 
20' (p = 0.003), 30' (p < 0.001), and 60' (p = 0.026) 
eccentricity.
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intervention, and to 92.63 (SD = 29.41) after twelve weeks. Thus, after six weeks of 
intervention, the area under the mean MPOD profiles increased approximately 11 
percent, and after twelve weeks, approximately 22 percent. Both iGMPOD (F2,6 = 9.12, p 
= 0.015, co2 = 0.57) and iLMPOD (F2,6 = 17.35, p 0.003, co2 = 0.73) significantly changed 
from baseline, according to analyses using an RB-3 design. A linear trend described the 
changes in iGMPOD (F = 16.74, p = 0.026, ©2 = 0.75) and iLMPOD (F = 39.75, p =
0.008, co2 = 0.83), with no 
departures from linearity.
The PP ratios for each 
subject increased after six weeks 
of intervention, and in three 
subjects, increased from visit two 
to visit three (see figure 21). A 
subjects-by-trial (RB-3) design 
revealed that PP ratios
Figure 21: Photophobia ratios (PP „tio) for the four significantly changed after twelve
subjects in Experiment Two at baseline and after six-
weeks (visit 2) and twelve-weeks (visit 3) o f lutein weeks of lutein intervention (F 2i6
intervention. The subjects’ mean PP ratio
IZZ2Visit2
Visrt3
0  8 .
ca 0.5
Q_ 0 .4 -
significantly increased from baseline (p = 0.011) 
according to a subjects-by-trials design.
= 10.41, p = 0.011, co =0.61). 
As was the case for MPOD, a 
linear trend appeared to describe the changes in PP ratio (F = 13.09, p = 0.036, co2 = 
0 .86).
Figure 22a-b shows the ten PP ratios and corresponding iGMPOD (a) and 
iLMPOD (b) from Experiment One, as well as the additional eight data points from
44
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Figure 22: The combined Gaussian (A) and 
Lorentzian (B) integrated macular pigment optical 
densities (MPOD) and photophobia ratios (PP ratio) 
observed in Experiment One and Experiment Two. 
Two linear fits are plotted in each panel. One linear 
fit shows the relationship observed in Experiment 
One (solid line), whereas the second shows the 
relationship between integrated MPOD and PP ratio 
for the combined data o f both experiments (dotted 
line). The repeat measures for the four subjects in 
Experiment Two are connected with solid lines.
Experiment Two. The linear fit 
from Experiment One and a linear 
fit of the data from both 
Experiments (n = 18) is plotted in 
the figures. The figure shows that 
the inclusion of data from 
Experiment Two has a slight 
impact on the linear fits. In both 
instances, there is a modest change 
in slope. If the subject with low 
MPOD is removed from the 
analyses, the linear fits of 
Experiment One (n = 9), and 
Experiment One plus Experiment 
Two (n = 17), are nearly identical, 
as shown in figure 23a-b.
Twenty-six random catch 
trials were performed while 
measuring PP ratios in both 
Experiments. An additional 
seventeen non-random catch trials 
were used by the Experimenter to 
better define subjects’ PP
45
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thresholds. The random catch 
trials had a hit:FA ratio of 12:1 
and the non-random catch trials 
had a hit:FA ratio of 7.5:1. Catch 
trials were not used in previous 
investigations of PP; as a result, 
an acceptable hit:FA ratio has not 
been determined. However, the 
hit:FA ratio observed in the 
current study was sufficiently 
high to suggest that PP thresholds 
can be measured reliably using 
the method of ascending limits 
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Figure 23: Linear relationships between photophobia 
ratio and integrated Gaussian (A) and Lorentzian (B) 
macular pigment optical density after removing 
subject CF’s data. Both panels contain linear fits of 
the data from Experiment One (solid line), as well as 
a linear fit o f the combined data from both 
Experiments (dotted line). The repeat measures for 
the four subjects in Experiment Two are connected 
with solid lines.
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CHAPTER VIII
DISCUSSION
The main finding of this project was that MPOD was associated with PP 
thresholds for a SW target relative to a MW target. In Experiment One, MPOD at three 
foveal loci was positively correlated with PP ratios, as was Gaussian and Lorentzian 
integrated MPOD. In Experiment Two, significant increases in MPOD after twelve 
weeks of lutein supplementation resulted in significant increases in PP ratios. 
Distribution o f Macular Pigment
The MPOD of the subjects in Experiment One is similar to previous research 
conducted using HFP. In several studies, Hammond et al. (1995; 1996a, b, c; 1997b) 
reported that MPOD at 30' eccentricity ranged between 0.10 and 0.57. For the small 
sample in Experiment One, MPOD ranged between 0.06 and 0.51 at 30' eccentricity. 
One consideration in comparing the results of the current project to those of Hammond 
and colleagues involves the spectral bandwidth of the test lights. In the studies by 
Hammond et al., the half-bandwidth of the test light was 8nm, whereas the half- 
bandwidth of the test light in the current project was 20nm. The broader spectral 
emission of test light used in the current study will result in a greater underestimation of 
MPOD at 460nm than the one used by Hammond and colleagues. Although it is 
negligible, another consideration is the peak wavelength of the test lights used by 
Hammond et al. In their studies, the peak wavelength of the test light was 460nm, the 
absorption peak of MP, whereas the test light in the Macular Metrics system has a peak
47
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wavelength of 458nm, 99.8% of the MP absorption peak. Regardless of the half­
bandwidth or peak wavelength of the test lights, the mean MPOD at 30' eccentricity for 
subjects in Experiment One is considerably higher than the mean MPOD reported in 
larger studies (n > 200) that used the Macular Metrics optical system. In a Midwest 
sample, Cuilla et al. (2001a) found that the mean MPOD at 30' was 0.211 (SD = 0.13). 
Similarly, the mean MPOD at 30' eccentricity in Hammond and Caruso-Avery’s 
Southwest sample was 0.22 (SD = 0.13). One possible explanation for the difference 
between these mean values and the values in this study is the retinal eccentricity of the 
parafoveal measure. In the current project, a sensation luminance unaffected by MP 
(reference) was obtained at six-degrees eccentricity. Cuilla et al. and Hammond and 
Caruso-Avery used a reference point of four-degrees eccentricity. If MP is present at 
four-degrees eccentricity, and some research supports this possibility (e.g., Robson et al., 
2003), a reference measure at this locus will be a spurious measure o f sensation 
luminance unaffected by MP. In other words, subjects’ MPOD at 30' eccentricity would 
be underestimated by their amount of MPOD at four-degrees. The spectral composition 
of the test target and eccentricity of the reference measure are just two factors that make 
between-study comparisons difficult. The ability to compare results between studies is 
further complicated by the manifold techniques used to measure MPOD in vivo. 
However, the range and mean MPOD in the current sample agrees well with values 
reported using other techniques and optical systems for nearly the same retinal loci (e.g., 
Kilbride et al., 1989; Beatty et al., 2001; Robson et al., 2003).
Few researchers have used HFP to measure MPOD across the fovea. One of the 
first was Wemer et al. (1987), who measured MPOD at six retinal loci in one observer to
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show that measures o f MPOD using centrally fixated targets are predicated on absorption 
at the edge of the test target. The majority of studies investigating the foveal distribution 
of MP used reflectometry techniques. A general finding across these studies is a high 
degree of similarity between the nasal and temporal MP profiles, as well as the inferior 
and superior MP profiles. This relationship, or symmetry, has also been noted in studies 
using HFP (Hammond et al., 1997b). The symmetry and distribution of MP across the 
fovea is often described using a Gaussian function. For example, Chen et al. (2001) 
found that the Gaussian function provided a good fit (mean R2 = 0.946, n = 54) for the 
MP profiles they obtained using fundus reflectometry. Hammond et al. (1997b) reported 
a mean R2 of 0.82 (n = 32) for the Gaussian fits of their subjects’ MPOD profiles. One 
indirect finding of the current study was that the Lorentzian distribution may provide a 
better estimate of the foveal distribution of MP compared to the commonly used 
Gaussian distribution. The mean Gaussian R2 for subjects in Experiment One was 0.957. 
For the Lorentzian fit, the mean coefficient of determination was 0.968. If the subject
with extremely low MPOD (and an uncharacteristic profile) is removed, the mean
• 2  2 Gaussian R is 0.973, and the mean Lorentzian R is 0.986. In both cases, the mean
Gaussian coefficient of determination is higher than those reported by Chen et al. (2001)
and Hammond et al. (1997b). This finding may be the result of chance or reflect reliable
subject performance in the current study. Regardless, the mean Lorentzian R2 is greater
than the Gaussian coefficient of determination, and the Lorentzian distribution provided a
better fit for eight of the ten subjects’ MPOD profiles in Experiment One. This suggests
that the Lorentzian distribution may provide a better model of MP across the fovea.
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The primary limitation of using HFP to measure MPOD profiles is the inability to 
measure MPOD at zero degrees eccentricity. To do so would require infinitesimally 
small centrally fixated targets. The smallest targets that can be used, however, that will 
allow for reliable results are on the order of 12' of visual angle. Thus, one benefit of 
fitting a MPOD profile with a Gaussian or Lorentzian distribution is the ability to 
estimate a peak MPOD. A measure of MPOD close to zero degrees was obtained by 
Hammond et al. (1997b). They measured MPOD using a centrally fixated 12' target and 
referred to this measure as peak MPOD, although it was technically a measure of MPOD 
at 6' eccentricity. They found that MPOD at 6' is approximately 39.6% higher than 
MPOD at 30' eccentricity. The authors also commented that a Gaussian fit frequently 
underestimated this peak. Chen et al. (2001) made the same observation. The mean 
estimated Gaussian peak (6' eccentricity) of subjects in Experiment One was 
approximately 27.8% higher than their mean MPOD at 30' eccentricity. Given the 
relationship between MPOD at 6' and 30' eccentricity observed by Hammond et al. 
(1997b), it appears that the Gaussian fit also underestimated peak MPOD in the current 
project. However, the Lorentzian estimated peak of subjects in Experiment One was 
34.7% higher than their MPOD at 30' eccentricity. This suggests that in addition to 
providing a better fit of the MPOD profile, the Lorentzian distribution may provide a 
better estimate of peak MPOD than does the Gaussian function.
Lutein Intervention and Macular Pigment Optical Density2
Since lutein and zeaxanthin were identified as the primary constituents of MP 
(Bone et al., 1985), numerous researchers have investigated the effects of lutein
2 Table 2 (Appendix B) summarizes the various interventions studies described in this section.
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intervention on MPOD. For example, Hammond et al. (1997a) measured MPOD at 30' 
eccentricity during a fifteen-week intervention in which subjects consumed 60g of 
spinach and 150g of com daily. The daily combined dose of lutein was approximately.
11.2mg, and the combined dose of zeaxanthin was approximately 0.6mg. The 
intervention provided about four to ten times as much lutein and zeaxanthin as an average 
diet (Brady et al., 1996; Tucker et al., 1999; Rock et al. 2002). After four weeks of 
intervention, mean MPOD significantly differed from baseline, increasing from 0.39 to 
0.50. In the current project, mean MPOD at 30' after twelve weeks of intervention 
increased from 0.34 to 0.42, slightly less than the mean change reported by Hammond et 
al. The increase in MPOD observed by Hammond et al. (1997a) appeared to plateau after 
four weeks of intervention. In contrast, MPOD in the current project increased linearly 
from baseline, such that the mean increase in MPOD after six weeks of intervention 
(0.04) was approximately half the increase observed at twelve weeks. Further, all four 
subjects consuming lutein appeared to respond to the intervention. Three of the ten 
subjects consuming spinach and com in Hammond et al.’s study failed to respond to the 
increased consumption of lutein and zeaxanthin.
In one “responder”—an individual who shows increases in MPOD as a result of 
increased intake of lutein—Hammond et al. (1997a) measured a detailed MPOD profile 
at baseline and again after 12 twelve weeks of dietary modification. Changes in MPOD 
were not uniform across the central retina. Instead, MPOD increased more in central loci 
than in peripheral loci. In this subject, MPOD increased 0.49 log units at 30' eccentricity, 
but only 0.08 log units at 3.5 degrees eccentricity. Although this subject appeared to be 
an “over” responder, given that the mean increase in MPOD for their sample was only
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about 0.10 log units at 30' eccentricity, the observed changes in MPOD across the central 
retina may represent the pattern in which lutein and zeaxanthin are deposited in the 
macula. In fact, the same effect was observed in the current study. Mean increases at 20' 
and 30' eccentricity were both approximately 0.08 log units, whereas the mean increases 
at 60' and 120' eccentricity were only 0.04 and 0.01 log units, respectively. The mean 
increase of the Gaussian estimated peak after twelve weeks of intervention was 0.08; for 
the Lorentzian peak it was 0.09. Interestingly, for all four subjects in the current study, 
the coefficient o f determination for both the Gaussian and Lorentzian fits of their MPOD 
profiles increased from baseline. Likewise, the post-intervention profile reported by 
Hammond et al. was better fit with a Gaussian (0.94 compared to 0.96) or Lorentzian 
(0.96 compared to 0.98) function than was the baseline profile. These findings suggest 
that MPOD does not increase uniformally across the fovea, but instead may follow a 
Gaussian or Lorentzian distribution.
One noteworthy difference between the current project and the study conducted 
by Hammond et al. (1997a) is the type of intervention: they used a food source of lutein, 
whereas a supplement was used in the current project. Although the changes in MPOD 
observed in the current study are similar to those of Hammond et al. (1997a) and other 
researchers that used natural sources of lutein (Johnson et al., 2000; Curran-Celentano et 
al., 2003), the supplement dosage of lutein required to achieve this effect was much 
greater. Few studies investigating the effects of lutein supplementation on MPOD found 
a significant effect using doses less than 20mg per day. For example, Lariviere et al. 
(2002) and Cardinault et al. (2003) failed to observe a significant change in MPOD after 
supplementation of 6mg and 9mg per day, respectively. One consideration, in addition to
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the dose size, was the length of intervention in these studies. Both studies measured 
MPOD after 5 weeks of intervention. It may be that changes in MPOD occur after longer 
intervention periods when supplements, as opposed to natural sources, are used at doses 
below lOmg per day. Preliminary results from an intervention study in which subjects 
consumed 2.4mg of lutein per day suggest that a small dose may significantly increase 
MPOD in about sixty-percent of subjects over a six-month period (Bone et al., 2003). In 
contrast, Berendschot et al. (2000) claimed a significant increase in MPOD occurred after 
only four weeks of intervention with lOmg of lutein per day. Their results, however, 
should be viewed with caution, as the reported significance of the effect is clearly not 
supported by the data in their figures. The mean increase in MPOD for their small 
sample (n = 8) was approximately 0.01 log units after four weeks. Aleman et al. (2001) 
investigated the effects of a six-month intervention on MPOD in normal and diseased 
eyes. Their subjects consumed 20mg of lutein supplements daily for six months and had 
their MPOD measured at baseline and again after the intervention period. MPOD was 
measured using a Macular Metrics densitometer like the one used in the present study 
except their smallest target had a visual angle of 20', as opposed to 40'. In normal 
subjects, MPOD significantly increased at 10' eccentricity, but not at the three additional 
loci. Conversely, mean MPOD in patients with retinitis pigmentosa and Usher syndrome 
significantly increased at all four loci. In both groups, mean MPOD increased 0.07 at 10' 
eccentricity, and in the diseased eyes, it increased 0.07, 0.08, and 0.04 at 30', 60' and 120' 
eccentricity, respectively. Using the same paradigm, Duncan et al. (2002) reported 
similar changes in MPOD at these four loci. The significant changes in MPOD reported 
by Aleman et al. (2001) and Duncan et al. (2002) agree well with the significant changes
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observed in the current study. If these researchers obtained more frequent measures of 
MPOD, a relationship between supplement dose and intervention length could possibly 
be estimated by comparing their data to the current project. It may be that the rate of 
increase of MPOD is identical in response to either 20mg or 30mg of lutein per day. This 
possibility is based on the findings of a few studies showing that increases in MPOD 
plateau after a certain point (e.g., Hammond et al., 1997a). Thus, the six-month profiles 
measured by Aleman et al. (2001) and Duncan et al. (2002) may represent MPOD that 
reached a saturation point after only twelve weeks of intervention. Alternatively, a 
longer intervention may be necessary to achieve a certain effect when using 20mg, 
compared to 30mg. For this possibility to be correct, the effects observed by Aleman et 
al. (2001) and Duncan et al. (2002) would have to occur after twelve-weeks of 
intervention, assuming the increases in these studies are similar to those in the current 
project.
Unfortunately, one cannot assess the interaction of dose and intervention length 
by comparing the data available to date (see Table 2). One study, however, investigated 
the effects of intervention length by obtaining frequent measures o f MPOD during 
supplementation. Landrum et al. (1997) measured MPOD at 45' eccentricity several 
times per week during supplementation with 30mg of lutein per day. Both subjects in 
this study responded to the treatment in a similar fashion. After a “lag” period of about 
three weeks, MPOD increased linearly throughout the 140 days of intervention. Their 
MPOD continued to increase for approximately thirty days after discontinuation of the 
supplement and remained at this elevated level for 200 days. The dosage used in the 
current project was selected based on the results of Landrum et al. (1997). In particular,
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their subjects’ MPOD increased approximately 0.15 log units after twelve weeks of 
intervention. This increase in MPOD is almost twice as high as the changes observed in 
the current study at two more central loci. If MPOD does increase more in central loci 
relative to peripheral loci (e.g., Hammond et al., 1997a), then one might expect that 
changes in MPOD at 20' and 30' eccentricity in the current project should have exceeded 
those of Landrum et al. (1997). The difference in effect size is difficult to reconcile given 
the similarities between the two studies (e.g., MPOD measured with HFP). However, 
one difference between the studies was the eccentricity of the reference measure of 
sensation luminance. In the current study, the extrafoveal measure was obtained at 
seven-degrees eccentricity, whereas Landrum et al. (1997) obtained a measure at eight- 
degrees eccentricity. Although it seems unlikely, if the mean MPOD of subjects in the 
current study increased 0.07 at six degrees eccentricity, then their veridical increase in 
MPOD would be about the same as Landrum et al.’s (1997) subjects. A more plausible 
explanation is that the four individuals in the current project may be “average” 
responders, whereas Landrum et al.’s (1997) two subjects maybe “over” responders, like 
the one described by Hammond et al. (1997a).
Taken together, the results of the various intervention studies suggest that lutein 
intervention, with either natural sources or supplements, can increase MPOD 
approximately 0.10 log units at loci inside one-degree eccentricity. While MPOD 
appears to increase more in some subjects relative to other responders, a few subjects do 
not appear to respond to intervention. In addition to the aforementioned dietary factors 
that affect lutein bioavailability, a few factors may limit the effects of lutein intervention 
on MPOD. As previously mentioned, the duration of lutein intervention may affect
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changes in MPOD. If MPOD does not increase during the first three to four weeks of 
intervention, as reported by Landrum et al. (1997), it is not surprising that studies with 
short intervention periods failed to observe a significant change in MPOD (e.g., Lariviere 
et al., 2002; Cardinault et al., 2003). Another possible limiting factor may be a subject’s 
baseline MPOD. Assuming the retina has a limited number of binding sites for 
carotenoids, it seems logical that individuals with high MPOD have fewer free binding 
sites than individuals with low MPOD. Thus, one might expect that an individual with 
low MPOD might respond more to intervention than an individual with high MPOD. In 
the current project, however, the increases in MPOD were the same for subject AW, who 
had a baseline MPOD of 0.51 at 30' eccentricity, and subject LS, who had a baseline 
MPOD of 0.15 at this eccentricity. The independence of baseline MPOD and subsequent 
increases in MPOD was also noted by Bone et al. (2003). A related limiting factor may 
be the ceiling effects observed in some studies. Hammond et al. (1997a), for example, 
found that MPOD appeared to plateau after four weeks of intervention, despite an 
additional month of dietary modification. It may be that retinal lutein and zeaxanthin 
have a saturation point, such that concentrations beyond this threshold fail to yield 
measurable increases in MPOD. In an in vitro model, Junghans et al. (2001) showed that 
as the lutein or zeaxanthin concentration in liposomes increased, light transmission 
through the medium decreased exponentially and eventually asymptotes. One might 
assume that such a saturation effect might not only affect measures of MPOD in an 
intervention study, but also PP.
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Macular Pigment Optical Density and Photophobia
The results of the current project suggest that MPOD plays a role in PP 
thresholds. In Experiment One, there was a significant linear relationship between PP 
ratio and MPOD at 20', 30' and 60' eccentricity. Individuals with higher MPOD at these 
loci required more SW light, relative to MW light, to experience PP in the fovea. In other 
words, the amount of SW light filtered by subjects’ MP was directly proportional to their 
PP ratios. The relationship between SW light absorption at 20' eccentricity and PP ratio 
was such that a ten-percent change in light transmission resulted in a 0.07 change in PP 
ratio. The correlation between PP ratio and MPOD was strongest for the 20' locus. 
Typically, individuals with high MPOD at central loci tend to have higher aggregate 
totals of MP. This relationship was true for nine of the ten subjects in Experiment One. 
The one subject who did not fit the correlation had relatively high MPOD at 60' and 120' 
eccentricity, compared to his MPOD at 20'. Such individuals demonstrate that measures 
of MPOD at a single locus cannot accurately estimate aggregate MP (Aleman et al.,
2001; Robson et al., 2003). In fact, this subject’s MPOD at 20' eccentricity was the third 
lowest in the sample, but his integrated MPOD was approximately the same as the 
subject with the highest MPOD at 20' eccentricity. Given the similarity in total MP 
screening for these two subjects, it is not surprising that they had similar PP ratios. A 
similar instance was noted by Stringham et al. (2004). In their study, two individuals had 
distinctly different MPOD profiles, but almost identical iLMPOD and PP thresholds.
This finding supports the idea that PP thresholds are affected by the aggregate screening 
of MP across the fovea (Stringham et al., 2003; 2004). Indeed, the correlations between 
PP ratio and iGMPOD and iLMPOD are stronger than the relationships between PP ratio
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and MPOD at any single locus. This difference in the strength of the correlation would 
undoubtedly be larger if the sample contained more individuals with broad or mesokurtic 
MPOD profiles. Still, the significant correlations between PP ratio and MPOD suggest 
that these two phenomena are related.
In Experiment Two, repeated measures of MPOD and PP ratio were obtained 
during an intervention with lutein supplements. After twelve-weeks of supplementation, 
MPOD at the three central loci, as well as iGMPOD and iLMPOD, significantly 
increased from baseline. The significant mean increase in SW light absorption resulted in 
a significant increase in mean PP ratio. This finding suggests that MP can affect PP 
thresholds for lights composed of wavelengths within its absorption spectrum. The 
relationship between increases in integrated MPOD and PP ratio was such that each ten- 
percent increase in integrated MPOD corresponded to a 0.05 increase in PP ratio. In 
terms of supplementation, a 0.05 increase in PP ratio was observed after subjects 
consumed a total of l,260mg of lutein. When the data from Experiment Two are added 
to the bivariate correlations in Experiment One, the strength of the relationship between 
PP ratio and iGMPOD (p < 0.0001) and iLMPOD (p < 0.0001) increases, although the 
additional eight data points are not independent measures. The function observed in 
Experiment One predicated the changes in PP ratio observed in Experiment Two. Thus, 
Experiment Two not only upheld the correlation measured in Experiment One, but 
demonstrated that MP may affect PP thresholds for SW lights.
The results of the current project may be relevant to some clinical conditions. As 
stated in the Introduction, PP is a common symptom of migraine headaches. The 
prevalence of recurrent migraine headaches may be as high as eighteen-percent of the
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population, and studies report that between 50 and 100 percent of patients experience PP 
(Vanagaite et al., 1997; Krymchantowski and Moreira 2001; Wober-Bingol et al., 2004 ). 
Lutein supplementation, or increased MP, may not prevent episodes of PP, but it may 
increase patients’ PP thresholds, allowing them to function (with visual comfort) under a 
broader range of light intensities. Certain eye diseases, such as AMD and cataract, are 
also associated with an increased incidence of PP. Lutein supplementation, then, may be 
beneficial for some patients to not only preserve ocular health, but increase PP 
thresholds. Relatedly, Olmedilla et al. (2001) showed that lutein supplementation (9mg 
per week) significantly improved glare thresholds in patients with cataract. The patient’s 
increased consumption of lutein likely increased their MP, attenuating the amount of S W 
light contributing to their glare thresholds post-treatment, relative to baseline. The post­
treatment glare thresholds were measured after an average of twenty months of 
intervention. One noteworthy finding in the current project was that PP thresholds could 
be significantly increased in less than three months. The collective results of Olmedilla 
et al. (2001) and the current project suggest that lutein supplementation may augment 
MP, and thereby increase thresholds of visual discomfort in patients.
Stringham et al. (2003) proposed that PP acts as an inherent mechanism to protect 
the retina from potentially dangerous levels of light. This postulation was predicated on 
their finding that PP thresholds were inversely related to wavelength, as is energy, and 
appeared to parallel the retinal damage function measured by Ham et al. (1976). Their 
inference seems reasonable, as one would expect a photo-protective mechanism to be 
biased towards more damaging wavelengths of light. Additionally, one might expect that 
PP magnitude, or degree of visual discomfort, might be correlated with the intensity of
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the light source. This assumption is based on the idea that some lights, while 
discomforting, may pose less risk for damage than more intense lights. In the former 
instance, an adequate photo-protective response may be a moderate squint, whereas the 
latter instance might require a large squint or eye closure. In the studies performed by 
Stringham et al. (2003,2004), some lights exceeded the 4:1 signal-to-noise ratio criterion 
for PP. Similarly, Deaver et al. (1996) showed that the length of the palpebral fissure 
was inversely related to luminance. These findings are further supported by measures of 
visual discomfort using scaling techniques (Sivak et al., 1999). If the magnitude or 
threshold of visual discomfort is affected by light intensity, as these studies suggest, it 
follows that an intervening filter should influence visual discomfort thresholds. In 
outdoor environments, for example, sunglasses may reduce visual discomfort or squint 
magnitude (Sliney, 2002). Likewise, the current project demonstrates that a SW filter, 
the MP, attenuates PP for SW lights. The results of Stringham et al. (2004) suggest that 
MP also affects thresholds for broad-band targets containing SW light (Stringham et al., 
2004). Given the influence of MP on PP, it may be that these two phenomena operate 
jointly to protect the retina from excessive levels of light. The MP may act as a static 
mechanism, constantly screening light in the more harmful range of the visible spectrum, 
whereas PP may act as a dynamic mechanism, occurring when retinal illuminance 
reaches or exceeds a certain risk threshold. In addition to protecting the retina from 
potential light-induced damage, MP and PP may act to mitigate transitory deficits of 
vision caused by afterimages. One anecdotal observation made by Stringham and 
colleagues in their research on PP (but not yet reported) was that SW lights tended to 
produce much longer afterimages than MW and LW lights containing less energy.
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CHAPTER IX
FUTURE DIRECTIONS
The results of the current project connected two phenomena that scientists have 
been investigating separately for more than a century. Still, numerous factors associated 
with MP and PP are unrealized. If MP improves visual function in diseased eyes or can 
inhibit the progression of retinal degeneration, it is important to determine the dose of 
carotenoids and intervention duration necessary to affect visual performance or reduce 
one’s risk for AMD. This issue is particularly important in light of the growing number 
of commercially available lutein supplements and the lack of a Food and Drug 
Administration Recommended Daily Allowance for lutein and zeaxanthin. If the retinal 
carotenoids are conditionally essential for the health of the macula (Semba & Dagnelie, 
2003), it is also important to determine why some individuals have extremely low 
MPOD, and relatedly, why some individuals show no retinal response to lutein 
intervention. These individuals may be at greater risk for developing macular disease.
The symptomatology of AMD, as well as several other age-related eye diseases, 
includes PP. Yet, most research investigating the clinical aspects of PP has focused on its 
prevalence in patients with migraines or neurological disorders. Using the methodology 
in the current project, it would be valuable to investigate the effects of lutein intervention 
on PP thresholds in a clinical sample. If the results of such a study are similar to the 
current project’s findings, lutein supplementation may be beneficial for individuals with 
frequent episodes of PP.
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Research investigating the stimulus conditions that induce PP might also be 
useful. If SW light is more likely to induce PP than MW or LW light, then an individual 
with frequent episodes o f PP might benefit from using household lighting devoid of SW 
light. Unfortunately, previous researchers, except for Stringham et al. (2003; 2004), 
failed to control or quantify retinal illuminance in their studies of the stimulus conditions 
that affect PP thresholds. Thus, it may be beneficial to retest some of their hypotheses 
using Maxwellian view optics. Additionally, several other conditions that might 
influence PP thresholds, such as the eye’s state of adaptation, are unexplored.
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CHAPTER X
CONCLUSION
Numerous studies suggest that retinal lutein and zeaxanthin, or MP, may play a 
role in retinal health and visual performance. The antioxidant properties of the retinal 
carotenoids may attenuate oxidative stress, while the absorbency of MP may mitigate 
light stress and concurrently reduce chromatic aberration. The light filtering properties of 
MP also appear to influence visual comfort. Specifically, the current project 
demonstrated that the MP increases the amount of light necessary to induce visual 
discomfort, or PP for SW targets. Should this prove beneficial, it has been demonstrated 
that twelve weeks of lutein supplementation can significantly increase MPOD, and as a 
result, PP thresholds.
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CHAPTER XIII
APPENDIX A
Table 1. Age, Sex, BMI and MPOD of Experiment One subjects.
Subject Sex Age BMI 20'
MPOD 
30' 60' 120'
JPS male 24 25.5 0.476 0.400 0.204 0.013
LS female 27 19.6 0.209 0.152 0.101 0.032
JMS male 32 24.4 0.354 0.258 0.179 0.016
AW male 30 22.6 0.656 0.513 0.195 0.056
MW female 29 21.3 0.415 0.314 0.213 0.126
MV female 21 22.2 0.569 0.397 0.199 0.065
ML male 29 29.6 0.410 0.376 0.260 0.101
CF female 26 20.0 0.143 0.059 0.061 0.077
SB female 21 26.6 0.513 0.394 0.230 0.019
BJ female 26 24.1 0.483 0.401 0.216 0.145
mean 26.5 23.6 0.423 0.326 0.186 0.065
SD 3.68 3.10 0.156 0.135 0.060 0.047
CV 13.8 13.1 36.8 41.4 32.2 72.3
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CHAPTER XIII
APPENDIX B










A3 10 11.2mg 15 30' 0.11 <0.05
B 2 30mg 20 45' 0.23 < 0.005
C4 8 lOmg 12 1.5° field 0.01 <0.001
D3 7 11.2mg 15 30' 0.07 <0.05












H6 21 2.4mg 26 45' 0.04 <0.05
I4'5 29 9mg 5 2° field nr nr
J3 6 214gg7 12 30' 0.11 <0.04
1 Study: A, Hammond et al (1997a); B, Landrum et al (1997); C, Berendschot et al (2000); D, Johnson et al 
(2000); E, Aleman et al (2001); F, Duncan et al (2002); G, Lariviere et al (2002); H, Bone et al (2003); I, 
Cardinault et al (2003); J, Curran-Celentano et al (2003)
2 nr = not reported.
3 Used a natural source o f  lutein (A, D: spinach + com; J: eggs), all other studies used lutein supplements.
4 Measured MPOD with reflectometry, yielding an average MPOD across a foveal area.
5 No significant change in MPOD at any eccentricity was observed.
6 Significant increases in MPOD were only observed for 12 o f the 21 subjects.
7 Calculated daily average of consuming six eggs per week.
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CHAPTER XIV
APPENDIX C
University of New Hampshire Institutional Review Board approval letter.
July 23, 2004
W enzel, Adam 
Psychology, Conant Hall 
25A E. Concord, Apt. # 3  
Dover, NH 03820
IRB # :  2990
Study: Im pact of Macular Pigment on Photophobia
Approval Date: 07/24/2003
The Institutional Review Board for the  Protection o f Human Subjects in Research (IRB) 
has reviewed and approved the  protocol for your study a s  Expedited as described in 
Title 45, Code of Federal Regulations (CFR), Part 46, Subsection 110.
Approval is granted to conduct your study as described in your protocol for 
one year from the approval date above. At the  end of th e  approval period, you will 
be  asked to  subm it a report with regard to  th e  involvement of hum an subjects in this 
study. If your study is still active, you may request an  extension of IRB approval.
Researchers who conduct studies involving hum an subjects have responsibilities as 
outlined in th e  attached docum ent, Responsibilities of Directors of Research Studies 
Involving Human Subjects. (This docum ent is also available a t  
http://w w w .unh.edu/osr/com oliance/IRB.htm l.') Please read this docum ent carefully 
before commencing your work involving hum an subjects.
If you have questions o r concerns abou t your study or this approval, please feel free to  
contact m e a t  603-862-2003 or Julie.sim pson@ unh.edu. Please refer to  th e  IRB #  
above in all correspondence related to this study. The IRB wishes you success with your 
research.




Research Conduct and Compliance Services, Office of Sponsored Research, Service 
Building, 51 College Road, Durham, NH 03824-3585 * Fax: 603-862-3564
U N I V E R S I T Y  o f  N E W  H A M P S H I R E
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